[
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=a31960e48931f8e5b447ac47d7f00e98d569eeeec6a7901daeadd5391f9b5dca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754068020,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 136229892,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a31960e48931f8e5b447ac47d7f00e98d569eeeec6a7901daeadd5391f9b5dca"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
    "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
    "url": "https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754046600,
      "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
      "id": 136166550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
      "url": "https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c"
    }
  },
  {
    "ts": null,
    "headline": "Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics",
    "summary": "The addition of Zurzuvae is expected to diversify and increase the company's revenue base and cash flow.",
    "url": "https://finnhub.io/api/news?id=d6a8a126ed634ce3a96fcf1bec40ef58a0fa3c2ef4829016e253ba53f5122e04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754046543,
      "headline": "Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics",
      "id": 136165951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The addition of Zurzuvae is expected to diversify and increase the company's revenue base and cash flow.",
      "url": "https://finnhub.io/api/news?id=d6a8a126ed634ce3a96fcf1bec40ef58a0fa3c2ef4829016e253ba53f5122e04"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus",
    "summary": "With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.",
    "url": "https://finnhub.io/api/news?id=25dd9c096cf792ce59ec238cbdaeeeb67cc7cdb50ac4be25ccd60fd34d09568b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754035200,
      "headline": "Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus",
      "id": 136165221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.",
      "url": "https://finnhub.io/api/news?id=25dd9c096cf792ce59ec238cbdaeeeb67cc7cdb50ac4be25ccd60fd34d09568b"
    }
  }
]